May 22, 2009

FAQs on Indian Competition Law

 

To facilitate competition in the Indian market, the Indian Government has enacted the new competition law called the Competition Act, 2002 (“Competition Act”) which is meant to replace the extant Monopolies and Restrictive Trade Practices Act, 1969 (“MRTP Act”) and provide institutional support to healthy and fair competition. The Competition Act seeks to prohibit anti-competitive agreements including cartels; prohibit abuse of dominant position and regulate combinations (mergers and amalgamations, and acquisitions).

 

As per the Business Standard news article dated May 21, 2009, the substantive provisions of the Competition Act relating to (i) prohibition of anti competitive agreements and (ii) abuse of dominance have been notified. Further, it is expected that the substantive provisions of the Competition Act with respect to regulations of combinations (mergers, amalgamations and acquisitions) will also be notified soon with the formation of the New Government. In light of the same, it becomes critical to understand the implications that the Competition Act will have on trade and mergers and acquisitions in India.

 

This M&A Lab captures frequently asked questions (“FAQs”) that both foreign and domestic acquirers may have with respect to Competition Act in India. For the sake of convenience and better understanding, these FAQs are divided into 4 parts – (Part I) Introduction; (Part II) Anti competitive agreements; (Part III) Abuse of dominance and (Part IV) Combinations.

 

For a detailed analysis of the commercial, legal, regulatory & tax considerations, please click here for the document.

 

As you would be aware, we have been providing regular information on latest legal developments. M&A Lab is our latest initiative to provide you in depth and knowledge based analysis of latest M&A deals. We will be happy to have your views / comments on our initiative. Please read the disclaimer carefully.

 

This article can be best viewed in Adobe Acrobat version 7.


 Team M&A
Ruchi Biyani / Abir Roy / Nishchal Joshipura / Kartik Ganapathy
You can direct your queries or comments to the team
 

You are welcome to connect with us at interesting conferences, seminars and events (more...

  VIDEO
Nishith Desai on Vodafone v/s Tax Department
Vyapak Desai on Foreign Investment Policy
Nishchal Joshipura on Satyam Maytas deal
Vyapak Desai on FII, FDI norms
Kartik Ganapathy on Ranbaxy Daiichi deal
Nishith Desai on Vodafone Controversy
Siddharth Shah on New FDI Norms
Siddharth Shah on P Notes
M&A Lab
Satyam: The Great Deception, February 9, 2009
HCL – Axon Deal Dissected, December 19, 2008
Zandu - Emami Hostile Turned Friendly M&A Deal Dissected, December 3, 2008
Ranbaxy - Daiichi Deal Dissected, November 14, 2008
 
  ARTICLES, HOTLINES & RESEARCH REPORTS
FCCB buybacks: Is the move enough?, The Economic Times, Ruchir Sinha & Nishchal Joshipura, January 6, 2009
Dual listed M&As: Live-in status in corporate world, The Economic Times, R Vaidhyanadhan Iyer & Vedant Shukla, December 17, 2008
SEBI goes the distance in easing takeover regulations, The Economic Times, Ruchir Sinha & Nishchal Joshipura, November 11, 2008
Is it time to bid adieu to ‘poison pills’? The Economic Times, R Vaidhyanadhan Iyer & Nishchal Joshipura, May 27, 2008
Amendments To Takeover Code – Oversight Or Intended?, November 7, 2008 
Mergers & Acquisitions in India  
Venture Capital at Crossroads
 
  SUBSCRIPTION

We update our clients by sending various hotlines. You can subscribe to one / more hotlines also. You can email us for registering yourself for any of the hotlines given below.

Corpsec Hotline
Tax Hotline
HR Hotline
iCe Hotline
Annual Budget
FII Hotline
Pharma Update
Infra Update
IP Update
Dispute Resolution Hotline


Unsubscribe
Feedback





Disclaimer: The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This M&A Lab provides general information existing at the time of preparation. The M&A Lab is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any  loss arising to any person acting or refraining from acting as a result of any material contained in this M&A Lab. It is recommended that professional advice be taken based on the specific facts and circumstances. This M&A Lab does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.